Press Releases Any 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 (-) 2012 2011 2010 2009 Reset 2012 December 5, 2012 arGEN-X announces grant of broad US patent covering its SIMPLE Antibody™ platform November 5, 2012 arGEN-X reveals the target and unique mechanism of action of its most advanced preclinical antibody at the PEGS Summit 2012 October 24, 2012 arGEN-X appoints Dr. David L. Lacey to its supervisory board October 3, 2012 RuiYi (formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a Novel anti-IL-6 Antibody May 13, 2012 Cambridge Healthtech Associates™ Announces arGEN-X as Inaugural Signature Award™ Winner April 23, 2012 arGEN-X granted first US patent covering its unique NHance™ technology March 18, 2012 arGEN-X appoints Alain Thibault as Chief Medical Officer and Koos Rasser as IP Counsel March 18, 2012 arGEN-X launches NHance™ technology to generate better human antibody therapies February 27, 2012 arGEN-X enters into a therapeutic antibody alliance with Shire February 7, 2012 arGEN-X advances a third therapeutic antibody program into preclinical development
